CBD Oil for Cancer

The Bottom Line

Cannabidiol (CBD) is the major non-psychoactive cannabinoid in cannabis. It has generated significant anticancer interest due to its ability to induce apoptosis in cancer cells, inhibit angiogenesis, suppress metastasis, and sensitize tumors to chemotherapy — all without the "high" of THC. However, the evidence base remains primarily preclinical (cell culture and animal studies). No large-scale randomized controlled trials have demonstrated CBD as an effective standalone cancer treatment. It may have a role as an adjunct for symptom management and potentially as a chemosensitizer, but claims of cures are not supported by human data.

CBD vs. THC — Key Differences

Understanding the distinction between CBD and THC is essential for evaluating cannabis in cancer:

• THC (delta-9-tetrahydrocannabinol): The psychoactive component. Binds CB1 receptors in the brain (producing euphoria, sedation). Also has anticancer effects but with psychoactive side effects. Medical cannabis typically involves THC-containing products.
• CBD (cannabidiol): Non-psychoactive. Does not bind CB1 receptors significantly. Has a very different safety profile. Generally better tolerated. CBD products derived from hemp (<0.3% THC) are federally legal in the US under the 2018 Farm Bill.
• Entourage effect: Whole-plant cannabis extracts (containing both CBD and THC plus other minor cannabinoids and terpenes) may have different effects than isolated CBD — a debated point in the field.

How CBD Works Against Cancer

• CB2 receptor activation: CBD has low affinity for CB2 receptors but can act as a partial agonist. CB2 is expressed primarily on immune cells; its activation in cancer cells triggers apoptosis through multiple pathways.
• ROS induction: CBD increases reactive oxygen species (ROS) in cancer cells beyond tolerable levels, causing oxidative damage and cell death. Normal cells can buffer moderate ROS increases; cancer cells cannot.
• Angiogenesis inhibition: Downregulates VEGF and other pro-angiogenic factors, disrupting tumor blood supply.
• Metastasis suppression: Inhibits invasion and migration of cancer cells by downregulating MMPs, uPA, and other metastasis-related proteins. Particularly well-studied in breast and lung cancer models.
• Cell cycle arrest: Stops cancer cells at G1 phase, preventing proliferation.
• Autophagy induction: Triggers autophagy — initially protective for cells, but prolonged autophagy in cancer cells leads to death.
• Chemosensitization: CBD has been shown to sensitize chemoresistant cancer cells to drugs like doxorubicin, temozolomide, and gemcitabine.
• Apoptosis via multiple pathways: TRPV2 channel activation, p53 upregulation, ER stress response, and Bcl-2 downregulation.

Key Preclinical Findings

Breast Cancer

CBD inhibits MDA-MB-231 and MCF-7 breast cancer cell proliferation, invasion, and metastasis. The mechanism involves downregulation of ID-1 (a key metastasis driver) and modulation of multiple signaling pathways (PI3K/Akt, MAPK/ERK). Animal models show reduced tumor growth and metastasis.

Glioblastoma

CBD has shown activity against glioblastoma cells (U87MG, patient-derived stem cells) in culture and animal models. Combination with standard temozolomide showed enhanced cell death. Notably, CBD may cross the blood-brain barrier — important for brain tumors.

Lung Cancer

In A549 lung cancer cells, CBD induces apoptosis and inhibits migration. Animal studies show reduced metastatic nodules in lung colonization models.

Colorectal Cancer

CBD inhibits proliferation in multiple colorectal cancer cell lines and reduces aberrant crypt foci in APC-mutant mouse models (relevant to familial adenomatous polyposis).

Clinical Evidence — What Exists

The honest answer is: limited. Most clinical trials have focused on CBD for cancer-related symptoms, not as an anticancer agent per se:

• Pain and symptom management: THC/CBD combinations (Sativex, for example) have shown benefit for cancer pain refractory to opioids.
• Chemotherapy-induced nausea: Nabilone and dronabinol (THC-based) are FDA-approved for CINV; CBD's role here is less established.
• Sleep and anxiety: CBD is widely used for sleep improvement and anxiety reduction in cancer patients — a legitimate supportive care use.
• Phase I/II trials for gliomas: A trial combining CBD with temozolomide in recurrent glioblastoma (NCT03590174) showed encouraging overall survival data — but this was not a randomized controlled trial.

Epidiolex — The Only FDA-Approved CBD

Epidiolex is a pharmaceutical-grade CBD extract (99% pure) approved by the FDA for two rare childhood epilepsy syndromes (Dravet syndrome and Lennox-Gastaut syndrome). While not approved for cancer, Epidiolex represents the best-characterized CBD product in humans. Key takeaways from its development:

• Safety profile: Generally well-tolerated up to 20 mg/kg/day
• Common side effects: Diarrhea, somnolence, fatigue, decreased appetite
• Drug interactions: CBD inhibits CYP450 enzymes (particularly CYP3A4 and CYP2C19), affecting levels of many drugs including some chemotherapies and antidepressants
• No liver toxicity at epilepsy doses (higher doses in cancer applications require monitoring)

Protocol Considerations

There is no established standard protocol for CBD in cancer. What is known from the literature:

• Dosing: Most preclinical studies use concentrations in the micromolar range (approximately 1–10 μM), achievable with oral doses of approximately 10–30 mg/kg in humans. OTC CBD products vary widely in actual content.
• Products: Hemp-derived CBD oil (<0.3% THC) is widely available. Full-spectrum products may have different effects. Isolate is pure CBD but may lack entourage effect.
• Lab testing: Only use products that provide third-party COA (certificate of analysis) confirming cannabinoid content and absence of contaminants.
• Duration: Chronic administration in preclinical studies suggests ongoing use may be needed for anticancer effects.

Safety and Drug Interactions

CBD has a relatively favorable safety profile but is not risk-free:

• Liver enzyme elevation: Dose-dependent, requires monitoring at higher doses
• Drug interactions (major): CBD inhibits CYP3A4, 2C19, 2D6, and others — can dangerously increase levels of many chemotherapy agents, anticoagulants, and other drugs
• Sedation: CNS depressant effects when combined with alcohol, benzodiazepines, or opioids
• Hypotension: Can cause orthostatic hypotension at higher doses
• Diarrhea and GI upset

Our Assessment

CBD has a compelling preclinical mechanism of action against cancer and is one of the better-studied phytocannabinoids. The ability to induce apoptosis, inhibit metastasis, and sensitize tumors to chemotherapy while having minimal toxicity is genuinely interesting. However, the absence of large RCTs in cancer patients is a significant limitation. Our grade reflects this: interesting science, potential adjunct value, but not established as an anticancer treatment. As a supportive care agent for anxiety, sleep, and pain in cancer patients, CBD has more established (though still limited) evidence. Worth discussing with an oncologist aware of the drug interaction profile, particularly for patients already on chemotherapy.

Sources

• PMC7665084: "Anticancer properties of CBD" — comprehensive review (2020)
• PMC6314177: CBD and breast cancer (2019)
• PMC6026218: CBD gliomas and temozolomide (2018)
• PMC10380366: Colorectal cancer CBD study (2023)
• ClinicalTrials.gov NCT03590174: CBD + temozolomide in glioblastoma
• PMC10466255: CBD pharmacokinetics and drug interactions (2023)
• FDA Epidiolex prescribing information